For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Tofacitinib - Ulcerative colitis
PAD Profile : Tofacitinib - Ulcerative colitis
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway.
The Surrey & North West Sussex Area Prescribing Committee (APC) recommends tofacitinib as a treatment option in adult patients with moderately to severely active ulcerative colitis in line with NICE TA 547 (November 2018)
Tofacitinib is a payment by results excluded medicine and initiation and subsequent monitoring of response will be by the gastroenterology specialist service. Blueteq forms for initiation and continuation will be available for completion by specialist teams.
Tofacitinib will be considered as RED on the traffic light system
Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.